These results demonstrate that JAK inhibition improves multiple immunodermatological conditions in DS, normalizes interferon scores, decreases levels of major pathogenic cytokines (e.g. TNF-α, IL-6), and reduces levels of pathogenic autoantibodies (e.g. anti-thyroid peroxidase [anti-TPO]). Here, IL6 is linked to Dravet syndrome.